Hybrid Systems Ltd. is exploiting the interface between polymer chemistry and biology to generate new products and tools for applications in areas as diverse as gene therapy, vaccination, agriculture and bioremediation.
The company's principal technology enables simple non-genetic coating of viruses, bacteria and spores, using hydrophilic polymers, to create safer and more versatile biological agents. There are several valuable applications of this platform technology. The company's primary focus is currently in the area of gene therapy for cancer. Hybrid Systems Ltd. is developing new, safer and more effective gene therapy treatments for ovarian and prostate cancer. The versatile polymer-coated viral and non-viral biological agents that have been generated are effective at evading immuno-detection and can be targeted to specific cells and tissues by incorporation of specific cellular receptor-binding moeties. These 'stealth' vectors should provide a safe and efficient means of directing genetic therapies to particular cell types, even when dispersed throughout the body, without affecting surrounding non-target tissues.